Cargando…

Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?

The number of pharmacokinetic (PK) models of meropenem is increasing. However, the daily role of these PK models in the clinic remains unclear, especially for critically ill patients. Therefore, we evaluated the published meropenem models on real-world ICU data to assess their suitability for use in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Letao, Sassen, Sebastiaan D. T., Ewoldt, Tim M. J., Abdulla, Alan, Hunfeld, Nicole G. M., Muller, Anouk E., de Winter, Brenda C. M., Endeman, Henrik, Koch, Birgit C. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951903/ https://www.ncbi.nlm.nih.gov/pubmed/36830294 http://dx.doi.org/10.3390/antibiotics12020383

Ejemplares similares

Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?
por: Li, Letao, et al.
Publicado: (2022)

Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
por: Ewoldt, Tim M J, et al.
Publicado: (2023)

Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)
por: Abdulla, Alan, et al.
Publicado: (2020)

Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Dose optimization of cefotaxime as pre‐emptive treatment in critically ill adult patients: A population pharmacokinetic study
por: Roelofsen, Eveline E., et al.
Publicado: (2022)

Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial
por: Abdulla, A., et al.
Publicado: (2020)

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19
por: Smeets, Tim J. L., et al.
Publicado: (2022)

Stability of 10 Beta-Lactam Antibiotics in Human Plasma at Different Storage Conditions
por: Bahmany, Soma, et al.
Publicado: (2023)

Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers
por: Edwina, Angela Elma, et al.
Publicado: (2023)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
por: Yang, Nan, et al.
Publicado: (2022)

Review of Scavenged Sampling for Sustainable Therapeutic Drug Monitoring: Do More With Less
por: Schouwenburg, Stef, et al.
Publicado: (2022)

Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain–Barré Syndrome
por: Fokkink, Willem Jan R., et al.
Publicado: (2022)

Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients
por: de Velde, Femke, et al.
Publicado: (2021)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

Using Residual Blood from the Arterial Blood Gas Test to Perform Therapeutic Drug Monitoring of Vancomycin: An Example of Good Clinical Practice Moving towards a Sustainable Intensive Care Unit
por: Smeets, T. J. L., et al.
Publicado: (2022)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Meropenem-Resistant Pandoraea Pneumonia in a Critically Ill Patient With COVID-19
por: Dlewati, Mohammad M, et al.
Publicado: (2021)

Meropenem PK/PD Variability and Renal Function: “We Go Together”
por: Angelini, Jacopo, et al.
Publicado: (2023)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Clearance of meropenem during continuous renal replacement therapy in critically ill patients
por: Thalhammer, F, et al.
Publicado: (1999)

Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
por: Goncalves-Pereira, João, et al.
Publicado: (2014)

Continuous infusion versus intermittent administration of meropenem in critically ill patients: a pilot study
por: Thalhammer, F, et al.
Publicado: (1999)

611. Meropenem Dosage Optimization in Critically Ill Patients Based on a Population Pharmacokinetic Approach.
por: Romano-Aguilar, Melissa, et al.
Publicado: (2022)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

Impact of High Body Weight on Mortality in Critically Ill Patients Receiving Meropenem for Pneumonia
por: Gao, Xiaofang, et al.
Publicado: (2019)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing
por: Roelofsen, Eveline E., et al.
Publicado: (2022)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients
por: Guo, Tingjie, et al.
Publicado: (2022)

Reply to: Higher PEEP in intubated COVID-19-associated ARDS patients? We are not sure
por: Somhorst, Peter, et al.
Publicado: (2022)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p8qbjivdr574iskorvrlod8993